4D pharma plc LON:DDDD a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following research update on its Clinical Development Programmes.
The Company currently has two programmes progressing towards the clinic, Blautix, for the treatment of Irritable Bowel Syndrome, and Thetanix, for the treatment of Paediatric Crohn’s Disease.
The Board of the Company is pleased to report that a dossier for Blautix has been submitted to Swissmedic (Swiss Agency for Therapeutic Products) and the EKNZ (Swiss ethics committee) in relation to a first in man study to be carried out in healthy volunteers and individuals exhibiting symptoms of IBS.
Thetanix also continues to progress towards a first in man study, to be carried out in Paediatric Crohn’s patients. Following a development programme to further optimise the Thetanix drug product, it is now anticipated that this trial will commence in H2 2015.
4D pharma plc LON:DDDD Chief Scientific Officer Dr. Alex Stevenson, commented “4D is at the forefront of the development of live biotherapeutics, a new class of drug designed to treat the underlying causes of disease rather than just the symptoms. A critical component of making live biotherapeutics a reality is the ability to rapidly translate candidates identified in the laboratory into pharmaceutical grade products that can be administered to patients. Over the last few months we have made tremendous progress in establishing a methodology that allows us to do just that. With Blautix and Thetanix approaching the clinic, we are applying this same methodology to our pipeline of novel live biotherapeutic treatments for additional indications, such as asthma and rheumatoid arthritis, in line with our goal of developing ground breaking treatments for a wide range of important diseases”.